STOCKHOLM, Sweden, Dec.10, 2017 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen’s assessment of market demand. The termination of the license wil…
Medivir Announces Janssen Decision to Terminate its Simeprevir License Effective June 2018
About M FundSITE ADMIN
